You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

humanized blocking antibody to CD40L

Showing 1 - 25 of 9,994
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +5 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +3 more
  • Los Angeles, California
    USC/Norris Comprehensive Cancer Center
Jan 31, 2023

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 25, 2022

Type 1 Diabetes Trial in Vancouver (Frexalimab, Placebo, Insulin)

Recruiting
  • Type 1 Diabetes Mellitus
  • Vancouver, British Columbia, Canada
    Investigational Site Number : 1240001
Oct 31, 2023

Liver Transplant Rejection Trial in Worldwide (CFZ533, Tacrolimus - MMF - corticosteroids)

Active, not recruiting
  • Liver Transplant Rejection
  • CFZ533
  • Tacrolimus - MMF - corticosteroids
  • Los Angeles, California
  • +28 more
Jan 17, 2023

Kidney Transplant Rejection Trial in Saint Louis, Richmond (AT-1501, Tacrolimus)

Recruiting
  • Kidney Transplant Rejection
  • Saint Louis, Missouri
  • +1 more
Aug 2, 2023

Kidney Transplant Rejection Trial in Montréal (AT-1501, Tacrolimus)

Enrolling by invitation
  • Kidney Transplant Rejection
  • Montréal, Quebec, Canada
    McGill University Health Care Centre
Nov 6, 2023

Recurrent Melanoma, Stage IV Melanoma Trial in Philadelphia (CD40 agonist mAb CP-870,893, tremelimumab, laboratory biomarker

Completed
  • Recurrent Melanoma
  • Stage IV Melanoma
  • CD40 agonist monoclonal antibody CP-870,893
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of The University of Pennsylvania
Apr 6, 2020

Kidney Transplant Trial in Montréal (AT-1501)

Recruiting
  • Kidney Transplant
  • Montréal, Quebec, Canada
    McGill University Health Care Centre
May 16, 2022

Brittle Type 1 Diabetes Trial (AT-1501 IV Infusion, Isolated cadaveric islet cells)

Not yet recruiting
  • Brittle Type 1 Diabetes Mellitus
  • AT-1501 IV Infusion
  • Isolated cadaveric islet cells
  • (no location specified)
Jul 27, 2022

Tumors Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a

Completed
  • Neoplasms
  • Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody
  • MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
  • Scottsdale, Arizona
  • +26 more
Mar 31, 2022

Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma Trial in Worldwide (Tocilizumab)

Recruiting
  • Adamantinomatous Craniopharyngioma
  • Recurrent Adamantinomatous Craniopharyngioma
  • Aurora, Colorado
  • +17 more
Jan 8, 2023

Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Richter's Transformation
  • Boston, Massachusetts
  • +1 more
Sep 12, 2023

Kidney Transplant Rejection Trial in Worldwide (CFZ533 - MMF - CS, Tacrolimus - MMF - +/- corticosteroids)

Completed
  • Kidney Transplant Rejection
  • CFZ533 - MMF - CS
  • Tacrolimus - MMF - +/- corticosteroids
  • Los Angeles, California
  • +73 more
Jun 8, 2022

The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT Trial (CD25

Not yet recruiting
  • The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
  • CD25 prophylaxis
  • (no location specified)
Jun 20, 2023

Salivary Gland Cancer Trial (vedicitumomab (Edisil, RC48), vedicitumomab in combination with pyrrolizidine, RC48 in combination

Not yet recruiting
  • Salivary Gland Cancer
  • vedicitumomab (Edisil, RC48）
  • +3 more
  • (no location specified)
Jun 9, 2023

Atopic Dermatitis Trial in Shanghai (MG-K10/Placebo)

Active, not recruiting
  • Atopic Dermatitis
  • MG-K10/Placebo
  • Shanghai, China
    Huashan Hospital Affiliated to Fudan University
Aug 31, 2023

Multiple Sclerosis Trial in Worldwide (SAR441344 IV, IV, SAR441344 SC)

Active, not recruiting
  • Multiple Sclerosis
  • SAR441344 IV
  • +4 more
  • Phoenix, Arizona
  • +47 more
Oct 10, 2022

Malignant Tumor of Digestive System Trial in Hanzhou (DR30303)

Recruiting
  • Malignant Neoplasm of Digestive System
  • Hanzhou, Zhejiang, China
    Sir Run Run Shaw Hospital，Zhejiang University School of Medicine
Nov 24, 2022

Lymphoma Trial (BYON4228 + Rituximab)

Not yet recruiting
  • Lymphoma
  • BYON4228 + Rituximab
  • (no location specified)
Feb 20, 2023

Type 1 Diabetes Trial in Edmonton (AT-1501)

Recruiting
  • Type 1 Diabetes Mellitus
  • Edmonton, Alberta, Canada
    University of Alberta
Sep 2, 2021

Thyroid Eye Disease Trial (Satralizumab, Placebo)

Not yet recruiting
  • Thyroid Eye Disease
  • (no location specified)
Oct 25, 2023

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Pancreatic Cancer Trial in Shanghai (Adebrelimab, mRNA tumor vaccines)

Not yet recruiting
  • Pancreatic Cancer
  • Shanghai, Shanghai, China
    Department of Pancreatic Surgery, Fudan University Shanghai Canc
Dec 4, 2023

Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • KRAS-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022